LONDON - Days after carving out its consumer health business, a slimmed down GSK delivered a strong second-quarter ...
LONDON (Reuters) -GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit growth, lifting the British company's shares by nearly 7% to ...
GSK has received the Food and Drug Administration’s approval for a prefilled syringe presentation of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster).
By Bhanvi Satija LONDON, April 29 (Reuters) - Strong first-quarter results under new GSK CEO Luke Miels on Wednesday failed to impress investors, who raised concerns that the British drugmaker's ...
Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate administration Co-administration of the RSV and shingles adjuvanted vaccines was ...
GSK raised its full-year financial outlook despite mixed results from its vaccines segment and declining sales of Shingrix. The British pharma giant reported total quarterly sales of £7.9 billion, up ...
Dynavax Technologies Corporation (NASDAQ:DVAX) announced topline results from Part 1 of its randomized, observer-blinded, and active-controlled Phase 1/2 clinical trial of Z-1018, a shingles vaccine ...
(RTTNews) - British drug maker GSK plc (GSK, GSK.L) announced Friday that the US Food and Drug Administration has accepted for review the regulatory application of a prefilled syringe presentation of ...
GSK GSK shares have lost 8.8% in a month, mainly because investors were disappointed with the company maintaining guidance ...
(RTTNews) - British drug major GSK plc (GSK, GSK.L) announced Thursday that the US Food and Drug Administration has approved a prefilled syringe presentation of Shingrix, GSK's Recombinant Zoster ...
Please provide your email address to receive an email when new articles are posted on . The original formulation of Shingrix consists of two separate vials combined by health care workers prior to ...